Subscribe Now

By entering these details you are signing up to receive our newsletter.

  • To use more accessibility options, please use a different browser such as Chrome or Firefox.
IN motion

Dr Sara ten Have discusses the environmental impact of peptides in drug development

7 June 2025
Interview by Nicola Miller, RARE Revolution insider, featuring Dr Sara ten Have, CEO, Origin Peptides
Dr Sara ten Have, director, Origin Peptides, on addressing the environmental impact of peptides in drug development

Origin Peptides want to revolutionise the peptide market, which according to their director Dr Sara ten Have they are doing via an approach that is “greener, cheaper and faster” as Sara explains in this extract of her interview

Dr Sara ten Have, director, Origin Peptides, on addressing the environmental impact of peptides.
Read Sara’s article “A new method of peptide synthesis may be the key to a greener future for pharma” here.
in motion

Related articles

INnovation

A new method of peptide synthesis may be the key to a greener future for pharma

By Shanzeh Mumtaz Ahmed
7 June 2025
Skip to content